Anticholinergic Use in Parkinson’s Disease: Practice Patterns in Patients with Cognitive Impairment
Objective: To explore utilization of anticholinergic medications using the Parkinson Foundation Quality Improvement Initiative (PF-QII) registry. Background: Recent publications have highlighted the association between anticholinergic…Effectiveness and Tolerability of Mirabegron and Behavioral Therapy in Patients with Parkinson’s Disease and Overactive Bladder: A Prospective, Randomized, Placebo-Controlled Pilot Study
Objective: To assess safety, tolerability, and efficacy of mirabegron and Pelvic floor Exercise (PFE)-based behavioral therapy for the treatment of overactive bladder (OAB) in patients…Anticholinergic Burden in Parkinson’s Disease Patients in India – A Hospital Based Study
Objective: To determine the cumulative anticholinergic burden in Indian Parkinson’s disease (PD) patients and to correlate the same with cognitive impairment and gait disturbance. Background:…Availability of Parkinson’s disease medicines in Ghana: a national survey
Objective: To determine the affordability, availability, geographic distribution and financing options of Parkinson’s disease (PD) medication in Ghana. Background: In sub-Saharan Africa, patients with PD…Effect of Medication Review on Reported Symptoms in Parkinson’s disease Patients
Objective: The objective was to analyse the effect of structured medication reviews (MR) in ambulatory PD patients on patient reported outcome measures (PROMS). Background: Patients…Does Anticholinergic Burden Affect the Outcomes in Patients Diagnosed with Parkinson’s Disease?
Objective: To explore the impact of an anticholinergic burden on various outcomes in Parkinson’s disease. Background: Over 600 different medications possess some anticholinergic effect.[1] There…Glycopyrrolate as inhalation for treating sialorrhea in Parkinson’s Disease
Objective: To evaluate the safety, tolerability and effect of glycopyrrolate inhalations in PD patients with sialorrhea. Background: Sialorrhea is reported in up to 60 percent…An oculogyric crisis after administation of alizapride: A tardive phenomenon?
Objective: We present a case of an oculogyric crisis (OGC) after administration of alizapride. Curious about this case is that the OGC only happened after…Preliminary Report on the MAESTRO Study: A Pilot Study of Mirabegron and Behavioral Modification including Pelvic Floor Exercise for Overactive Bladder in Parkinson Disease.
Objective: To report enrollment and tolerability data of mirabegron treatment in PD patients with OAB. Background: Lower urinary tract symptoms in PD have an estimated…Selective M4 antagonism potentiates L-DOPA-induced dyskinesia in MPTP-treated common marmosets
Objective: To determine the role of M4 muscarinic receptors in the expression of L-DOPA-induced dyskinesia (LID) and dystonia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets. Background:…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.